Business
Genflow Biosciences PLC Announces Director Dealings
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...
About this update from Genflow Biosciences Plc
[{"type":"text","content":"THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.","length":415,"tagName":"p"},{"type":"text","content":"LONDON, UNITED KINGDOM / ACCESS Newswire / March 28, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") the only longevity company listed in Europe, is pleased to announce that it has been notified that Dr. Eric Leire, CEO of the Company, has today purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the open market.","length":402,"tagName":"p"},{"type":"text","content":"Details of the transaction are set out below:","length":45,"tagName":"p"},{"type":"table","headerItems":[{"style":"padding:.75pt;","val":[{"type":"text","content":"Name","length":4,"tagName":"p","attribs":{}}]},{"style":"padding:.75pt;","val":[{"type":"text","content":"Dr. Eric Leire","length":14,"tagName":"p","attribs":{}}]}],"items":[{"val":[{"style":"padding:.75pt;","val":[{"type":"text","content":"Position","length":8,"tagName":"p","attribs":{}}]},{"style":"padding:.75pt;","val":[{"type":"text","content":"Chief Executive Officer","length":23,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"padding:.75pt;","val":[{"type":"text","content":"Date of Purchase","length":16,"tagName":"p","attribs":{}}]},{"style":"padding:.75pt;","val":[{"type":"text","content":"27 March 2025","length":13,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"padding:.75pt;","val":[{"type":"text","content":"Number of Ordinary Shares Purchased","length":35,"tagName":"p","attribs":{}}]},{"style":"padding:.75pt;","val":[{"type":"text","content":"2,100,000","length":9,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"padding:.75pt;","val":[{"type":"text","content":"Price per Ordinary Share","length":24,"tagName":"p","attribs":{}}]},{"style":"padding:.75pt;","val":[{"type":"text","content":"1.15p","length":5,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"padding:.75pt;","val":[{"type":"text","content":"Total Consideration","length":19,"tagName"...